Calpain-cleavage of α-synuclein -: Connecting proteolytic processing to disease-linked aggregation

被引:193
作者
Dufty, Brian M.
Warner, Lisa R.
Hou, Sheng T.
Jiang, Susan X.
Gomez-Isla, Teresa
Leenhouts, Kristen M.
Oxford, Julia T.
Feany, Mel B.
Masliah, Eliezer
Rohn, Troy T.
机构
[1] Boise State Univ, Dept Biol, Boise, ID 83725 USA
[2] Natl Res Council Canada, Inst Biol Sci, Expt Therapeut Lab, Ottawa, ON, Canada
[3] Hosp Santa Creu & Sant Pau, Neurol Serv, Unidad Memoria, Barcelona, Spain
[4] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[5] Univ Calif San Diego, Dept Neurosci & Neuropathol, La Jolla, CA 92093 USA
关键词
D O I
10.2353/ajpath.2007.061232
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are both characterized pathologically by the presence of neuronal inclusions termed Lewy bodies (LBs). A common feature found in LBs are aggregates of alpha-synuclein (alpha-Syn), and although it is now recognized that a-Syn is the major building block for these toxic filaments, the mechanism of how this occurs remains unknown. In the present study, we demonstrate that proteolytic processing of alpha-Syn by the protease calpain I leads to the formation of aggregated high-molecular weight species and adoption of a beta-sheet structure. To determine whether calpain-cleavage of alpha-Syn occurs in PD and DLB, we designed site-directed calpain-cleavage antibodies to alpha-Syn and tested their utility in several animal model systems. Detection of calpain-cleaved alpha-Syn was evident in mouse models of cerebral ischemia and PD and in a Drosophila model of PD. In the human PD and DLB brain, calpain-cleaved alpha-Syn antibodies immunolabeled LBs and neurites in the substantia nigra. Moreover, calpain-cleaved alpha-Syn fragments identified within LBs colocalized with activated calpain. in neurons of the PD and DLB brains. These findings suggest that calpain I may participate in the disease-linked aggregation of alpha-Syn in various alpha-synucleinopathies.
引用
收藏
页码:1725 / 1738
页数:14
相关论文
共 50 条
[1]   α-Synuclein and the Parkinson's disease-related mutant Ala53Thr-α-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells [J].
Ancolio, K ;
da Costa, CA ;
Uéda, K ;
Checler, F .
NEUROSCIENCE LETTERS, 2000, 285 (02) :79-82
[2]  
Baba M, 1998, AM J PATHOL, V152, P879
[3]  
Barber R, 2001, INT J GERIATR PSYCH, V16, pS12, DOI 10.1002/1099-1166(200112)16:1+<::AID-GPS562>3.0.CO
[4]  
2-3
[5]   Degradation of α-synuclein by proteasome [J].
Bennett, MC ;
Bishop, JF ;
Leng, Y ;
Chock, PB ;
Chase, TN ;
Mouradian, MM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (48) :33855-33858
[6]   Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease [J].
Blandini, F ;
Sinforiani, E ;
Pacchetti, C ;
Samuele, A ;
Bazzini, E ;
Zangaglia, R ;
Nappi, G ;
Martignoni, E .
NEUROLOGY, 2006, 66 (04) :529-534
[7]   The solubility of α-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease [J].
Campbell, BCV ;
McLean, CA ;
Culvenor, JG ;
Gai, WP ;
Blumbergs, PC ;
Jäkälä, P ;
Beyreuther, K ;
Masters, CL ;
Li, QX .
JOURNAL OF NEUROCHEMISTRY, 2001, 76 (01) :87-96
[8]   α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease [J].
Chen, L ;
Feany, MB .
NATURE NEUROSCIENCE, 2005, 8 (05) :657-663
[9]   The biochemistry of Parkinson's disease [J].
Cookson, MR .
ANNUAL REVIEW OF BIOCHEMISTRY, 2005, 74 :29-52
[10]  
Crocker SJ, 2003, J NEUROSCI, V23, P4081